Drug-induced corneal deposits: an up-to-date review

被引:11
|
作者
Sahyoun, Jean-Yves [1 ]
Sabeti, Saama [2 ]
Robert, Marie-Claude [1 ]
机构
[1] Ctr Hosp Univ Montreal, Ophthalmol, Montreal, PQ, Canada
[2] Univ Ottawa, Ophthalmol, Ottawa, ON, Canada
来源
BMJ OPEN OPHTHALMOLOGY | 2022年 / 7卷 / 01期
关键词
VIVO CONFOCAL MICROSCOPY; GROWTH-FACTOR RECEPTOR; ENDOTHELIAL DEPOSITS; SKIN PIGMENTATION; OCULAR TOXICITY; RIFABUTIN PROPHYLAXIS; CRYSTALLINE DEPOSITS; CLOFAZIMINE THERAPY; KERATOPATHY; AMIODARONE;
D O I
10.1136/bmjophth-2021-000943
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
This review assesses different clinical aspects of the various known drug-induced corneal deposits, based on the corneal layer involved (epithelium, stroma and/or endothelium), and based on the drug class. The most well-known condition caused by drug deposits is vortex keratopathy, or corneal verticillata, which is a whorl-like opacity in the corneal epithelium. Vortex keratopathy is commonly caused by certain cationic amphiphilic drugs such as amiodarone, antimalarials, suramin, tamoxifen, chlorpromazine and non-steroidal anti-inflammatory drugs. These deposits usually occur once a certain dose of the drug is reached. Most cases present with mild to moderate symptoms with minimal visual impairment. Most of these deposits resolve automatically, after months to years of drug cessation. Notably, other drug classes can cause deposits in all three layers of the cornea. Chlorpromazine, gold, rifabutin, indomethacin and tyrosine kinase inhibitors can cause stromal deposits, with reduced visual acuity when the anterior stroma is involved. Chlorpromazine and rifabutin can also cause deposits in the endothelial layer of the cornea. Regardless of the type of corneal deposit, local therapies such as topical lubricants or corticosteroids may help improve symptoms. Drug cessation or modification can also be helpful but should be weighed against the systemic risks of the underlying disease.
引用
收藏
页数:9
相关论文
共 50 条
  • [1] Antituberculosis drug-induced hepatotoxicity: Concise up-to-date review
    Tostmann, Alma
    Boeree, Martin J.
    Aarnoutse, Rob E.
    de lange, Wiel C. M.
    van der Ven, Andre J. A. M.
    Dekhuijzen, Richard
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2008, 23 (02) : 192 - 202
  • [2] Neurotoxicity Induced by Mephedrone: An up-to-date Review
    Pantano, Flaminia
    Tittarelli, Roberta
    Mannocchi, Giulio
    Pacifici, Roberta
    di Luca, Alessandro
    Busardo, Francesco Paolo
    Marinelli, Enrico
    CURRENT NEUROPHARMACOLOGY, 2017, 15 (05) : 738 - 749
  • [3] Up-to-date drug information
    Repchinsky, C
    CANADIAN FAMILY PHYSICIAN, 2001, 47 : 1545 - 1545
  • [4] Tumor-Induced Osteomalacia: an Up-to-Date Review
    Hautmann, Anke H.
    Hautmann, Matthias G.
    Koelbl, Oliver
    Herr, Wolfgang
    Fleck, Martin
    CURRENT RHEUMATOLOGY REPORTS, 2015, 17 (06)
  • [5] Tumor-Induced Osteomalacia: an Up-to-Date Review
    Anke H. Hautmann
    Matthias G. Hautmann
    Oliver Kölbl
    Wolfgang Herr
    Martin Fleck
    Current Rheumatology Reports, 2015, 17
  • [6] Phlebolymphedema: an up-to-date review
    Ulloa, Jorge H.
    Cifuentes, Sebastian
    Figueroa, Valentin
    Van Uden, Emelyn
    Bravo, Javier A.
    Amore, Miguel
    Ramirez, Jairo
    PHLEBOLYMPHOLOGY, 2021, 28 (02) : 49 - 60
  • [7] Advances in Antifungal Drug Development: An Up-To-Date Mini Review
    Bouz, Ghada
    Dolezal, Martin
    PHARMACEUTICALS, 2021, 14 (12)
  • [8] An up-to-date approach to drug polymorphism
    Toscani, S
    THERMOCHIMICA ACTA, 1998, 321 (1-2) : 73 - 79
  • [9] Aggregation-induced emission of azines: An up-to-date review
    Kagatikar, Sneha
    Sunil, Dhanya
    JOURNAL OF MOLECULAR LIQUIDS, 2019, 292
  • [10] VORICONAZOLE-INDUCED HEPATOTOXICITY CONCISE UP-TO-DATE REVIEW
    Ertem, Ozge
    Gumustekin, Mukaddes
    JOURNAL OF BASIC AND CLINICAL HEALTH SCIENCES, 2022, 6 (01): : 325 - 334